GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (STU:2RH) » Definitions » Institutional Ownership

Redhill Biopharma (STU:2RH) Institutional Ownership : 0.00% (As of Apr. 13, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Redhill Biopharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Redhill Biopharma's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Redhill Biopharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Redhill Biopharma's Float Percentage Of Total Shares Outstanding is 0.00%.


Redhill Biopharma Institutional Ownership Historical Data

The historical data trend for Redhill Biopharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Institutional Ownership Chart

Redhill Biopharma Historical Data

The historical data trend for Redhill Biopharma can be seen below:

2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31
Institutional Ownership 0.10 0.09 0.09 0.07 0.05 0.04 0.04 0.02 0.02 0.01

Redhill Biopharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Redhill Biopharma Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

Redhill Biopharma Headlines

No Headlines